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ABSTRACT 
 
Over the past 60 years, the Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used worldwide 
to prevent tuberculosis (TB). However, BCG has shown a very variable efficacy in different trials, showing a 
wide range of protection in adults against pulmonary TB. Previous studies indicate that this failure is related 
to pre-existing immune response to antigens that are common to environmental sources of mycobacterial 
antigens and Mycobacterium tuberculosis. Specifically, two different mechanisms have been hypothesized: 
the masking, (previous sensitization confers some level of protection against TB), and the blocking (previous 
immune response prevent vaccine taking of a new TB vaccine), effects. In this work we introduce a series of 
models to discriminate between masking and blocking mechanisms and address their relative likelihood. The 
application of our models to interpret the results coming from the BCG-REVAC clinical trials, specifically 
designed for the study of sources of efficacy variability yields estimates that are consistent with high levels of 
blocking (41% in Manaus -95% C.I. [14%-68%]- and 96% in Salvador -95% C.I. [52%-100%]-), and no 
support for masking to play any relevant role in modifying vaccine’s efficacy either alone or aside blocking. 
The quantification of these effects around a plausible model constitutes a relevant step towards impact 
evaluation of novel anti-tuberculosis vaccines, which are susceptible of being affected by similar effects if 
applied on individuals previously exposed to mycobacterial antigens. 
 
 
INTRODUCTION 
 
Despite all the efforts in the fight against TB accomplished during the last decades, the disease still remains 
a major cause of morbidity and mortality worldwide, being responsible for a million and a half deaths per year 
all around the world [1]. The increasing emergence of multi drug and extremely drug resistant strains [2] or 
the association between TB and VIH [3,4] constitute serious epidemiological threats that evidence the 
necessity of further public health measures and pharmacological resources against the disease. 
 
Among all the possible epidemiological interventions that could contribute to the desired goal of TB 
eradication, the introduction of a novel preventive vaccine is currently thought to be able to offer the highest 
and most immediate impact on disease burden reduction, since the efficacy of the current TB vaccine BCG is 
reduced, and only consistent in protecting infants, specially from the most severe forms of meningeal and 
miliary TB [5]. Accordingly, nowadays there exist more than fifteen different research teams worldwide 
developing as many novel experimental vaccine candidates designed to substitute BCG, or, at least, to be 
applied as a booster in BCG vaccinated individuals in order to enhance the protective effects of the old 
vaccine [6]. 
 
BCG fails to provide consistent protection to the pulmonary forms of the disease, especially in adults [7], who 
are the main contributors of overall disease spreading. Consequently, an accurate evaluation of the BCG 
impact under different conditions – population susceptibility, geography, environmental exposure, etc- is 
essential: firstly, it will allow to assess the efficiency of BCG as a reference vaccine and secondly, it will 
provide new guidelines and methodological tools to better evaluate the potential efficacy of the newly 
developed TB vaccines. The highly variable and apparently inconsistent results obtained in BCG’s efficacy 
tests and meta-analysis have been subject of intense scientific controversy [5,8]; and the use of BCG during 
the 20th century has been largely argued [9,10].  
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The hypothesized causes underlying the observed variability of BCG efficacy in different settings include 
differences between the BCG strains [11], genetic, epi-genetic or socio-economical differences between 
populations, study quality, parasitic co-infections, etc [6]. In addition, multi-variate meta-analysis of BCG 
efficacy determination studies consistently determine that latitude is a variable showing a  direct correlation 
with BCG performance [10,12,13,14], pointing to the existence of latitude-driven mechanisms influencing it, 
rather than other possible explanations related, for example, to the ethnicity of the tested populations [15]. 
Among these possible mechanisms, the hypothesis that agglutinates a greater consensus points to the 
existence of a complex, latitude-dependent immunological process of environmental sensitization (ES) to 
mycobacterial antigens which might interfere with the observed action of BCG vaccine in different ways. The 
hypothesis of ES being the source of BCG efficacy variability has been backed up by different 
epidemiological observations [5,16,17,18]. 
 
ES is thought to have its origin in the exposure of individuals either to non tuberculous mycobacteriae (NTM) 
-whose antigenic similarity to MTB [19,20] is able to cause cross reactivity in the human immune system 
[21,22]-, or to the reservoir of latent infection of MTB itself (and other closely related bacteria within the MTB-
complex). Even if the diversity among the different putative sources of ES (both in terms of prevalence 
depending on latitude and in terms of cross reactivity levels) portraits a complex landscape that makes 
specially ventured to attribute the geographical patterns of BCG efficacy variation to a single factor (as for 
example, to an hypothetical increase in NTM prevalence levels next to the equator [21,22,23], which has 
been demonstrated to be inaccurate for some species [24]), it seems clear that overall levels of ES increase 
both with closeness to equator and subjects’ age at the time of vaccination. 
 
Two different mechanisms have been theorized on how this exposition to mycobacteriae would affect the 
response of the host to a vaccine like BCG [25]. The masking hypothesis postulates that environmental 
sensitization confers a significant protection against TB in such a way that a vaccine can barely offer an 
additional level of protection [25,26]. Another possible effect is that prior ES may trigger an immune 
response capable of blocking the assimilation of the vaccine by the host, either if it’s a live-attenuated 
vaccine or if it’s a booster. This is known as the blocking hypothesis [25,27]. These two effects have the 
potential to explain, to a large extent, the variability observed in the trials performed, that is, both the 
dependence of BCG efficacy on age at the time of vaccination – as an individual gets older its exposition to 
mycobacteriae increases – and its geographical variations. Relevantly enough, if BCG were affected by 
masking, the temporal patterns of observed protection loss after vaccination of newborns would be different 
in different areas subject to different levels of ES. That would not be the case for blocking, for which it would 
be enough to apply the vaccine right after birth, when ES has not taken place, no matter the geographical 
location. 
 
In order to elucidate which of these mechanisms drives the observed variability between different studies, 
and up to what extent, BCG-REVAC trials were designed to discriminate these two effects on BCG 
performance when applied on individuals of dissimilar ages in different cities of different latitudes within the 
same country (Salvador and Manaus, in Brazil) [8,28,29]. After the analysis of BCG-REVAC trials, Barreto et 
al. observed that the efficacy of the vaccine, when applied to newborns and measured later in life did not 
show a strong geographic variation, at variance to what it was observed when BCG was applied at school 
age [8]. In addition, for BCG revaccination at school age, protection was modest in Salvador and absent in 
Manaus [8]. These observations suggested that blocking plays a more relevant role than masking on 
explaining BCG efficacy variations. However, even if the design of BCG-REVAC trials allowed to qualitatively 
asses the greater relevance of the blocking effect as compared to masking, no actual quantification of these 
two effects and their relative role has been provided up to now. In this sense, after the work by the BCG-
REVAC consortium, several questions remain unanswered, as we do not know 1) what’s the relative 
likelihood of both hypothetical mechanisms when trying to explain the observed results of the trial, 2) how 
much predictive power would a full model containing both effects gain with respect to single effects scenarios 
(masking or blocking alone) 3) whether significantly different combinations of masking and blocking strengths 
could be similarly compatible with the observations derived from the trials or not, and, very relevantly, 4) 
what are the intensities of blocking and masking effects, and their confidence intervals, yielding a most 
significant agreement with the data. 
 
In this paper, we introduce a family of mathematical models to interpret the results from BCG-REVAC under 
the light of masking and blocking effects, in order to contribute to answer the aforementioned questions 
within the limitations imposed to the reduced statistical power derived from the reduced number of trials 
studied. By confronting our model against the results of the BCG-revac studies, we are able to measure up 
to which extent these effects are sufficient to explain the efficacies measured [8], as well as to quantify the 
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specific masking, blocking and immunity waning effects yielding best fit estimates for the efficacies 
measured, comparing to this end the likelihoods of three different modeling scenarios: a first model in which 
both effects take place concurrently, a second model only considering blocking and a third one containing 
only masking. It is worth noticing that translating the trials results into quantitative estimations of blocking and 
masking strengths is a relevant step that enables mathematical models of disease spreading aimed at 
evaluating vaccine impacts to take into account these effects, both in what regards the dependence of BCG 
efficacy itself on individuals’ age and geographical areas and also in what concerns the plausible ranges of 
blocking and masking that any novel vaccine might eventually suffer. 
 
 
METHODS  
 
Data analyzed: the Brazilian BCG-REVAC clinical trials 
 
BCG-REVAC consisted of a set of cluster-randomized trials involving more than 200,000 school-aged 
children in the Brazilian cities of Manaus and Salvador, whose principal aim was evaluating the effectiveness 
of BCG under different vaccination protocols. 
 
 
 
Figure 1: Best fit estimates for each trial by models 1, 2 and 3 (yellow, blue and green 
dots, respectively) for the trials conducted in the BCG-revac study. The colormap 
represents the probability of obtaining a more extreme value of the efficacy, according to 
the distributions considered. The probability of zero marks the central estimate (red, 
continuous line) while the dashed red lines mark the 95% C.I. reported by [6]. 
 
 
The enrolled population of the study consisted of non-infected school children between 7 and 14 years old at 
the moment of randomization. Within this population, individuals presenting a positive BCG scar are 
separated from the rest, distinguishing, this way, the enrolled individuals who were vaccinated at birth from 
those who were not. Each group is then split into an intervention and a control group; individuals in the 
intervention group were vaccinated within the context of the trial. Summing up, there are 4 cohorts in each 
city: non vaccinated (1), vaccinated after birth (2), firstly vaccinated at school age during the trial (3), and 
revaccinated, after a first dose applied after birth, in the trial too (4). Upon such classification of enrolled 
individuals in cohorts, the effectiveness of BCG vaccination strategies was measured by comparing the TB 
incidence rate within an end-point associated to active disease in the four cohorts, according to three 
different types of trials: Trial I: BCG at birth vs. no intervention (cohort 2 vs. 1). Trial II: BCG first dose at 
school age vs. no intervention (cohort 3 vs. 1). Trial III: revaccination at school age vs. first dose at birth only 
(cohort 4 vs. 2). 
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A model to describe BCG efficacy variation: masking, blocking and immunity waning.  
 
The six clinical trials conducted within the framework of BCG-REVAC study –three types of trials per two 
cities- output efficacies that span from 1% to 40% protection (see figure 1, red continuous lines). In order to 
explain this variability we propose a model according to which the different protection levels found in each of 
the four cohorts in the study, schematically shown in figure 2, result from the interplay between the intrinsic 
vaccine efficacy, its temporal waning patterns, masking and blocking effects. These three mechanisms of 
vaccine protection shifts are ultimately responsible for vaccine’s performance variation, either in space (i.e. 
between the two cities of the study) or in time, as function of individuals’ age at the moment of vaccination 
and/or the time passed between vaccination and observation.  
 
 
 
 
 
Figure 2: Scheme of the different contributions to the disease risk for each cohort. 
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First of all, in absence of masking or blocking, a naive vaccinated individual will receive a protection level, 
right after vaccination, that we call 
 
e(0). As time after vaccination goes by, this protection level will wane up 
to 
 
e(t) < e(0) , generally speaking. This implies that, if we deal with a population in which the incidence rate of 
new TB cases per unit time is equal to 
 
x ; 
 
t  years after vaccination this rate is modified to 
 
1! e(t)( )x , 
provided that no additional effects take place. Taking that into account, a protective vaccine will have positive 
efficacy values 
 
e(t )! (0,1], being also possible for a (failed) vaccine to have a negative efficacy if it augments 
the disease risk among vaccinated individuals instead of reducing it. In our model, the time waning patterns 
of the intrinsic vaccine efficacy do not depend on the geographical area, but just on time since vaccination, 
which approximately is, in average, 4.5 years for school age vaccination (cohort 3) and 16 years for newborn 
vaccination (cohort 2), which implies the consideration of two intrinsic efficacy parameters: 
 
e(4.5)  and 
 
e(16) .  
 
Besides vaccination, ES can also support protection against disease through the masking mechanism. The 
masking level, denoted by 
 
m , is a protection parameter formally equivalent to the intrinsic vaccine efficacy 
(thus verifying 
 
m ! (0,1] for a protective effect, and negative otherwise), whose effects are suffered by initially 
naive, non-vaccinated individuals subject to ES. Thus, in principle, the longer the time an individual has been 
exposed to ES –i.e. the older the individual is at the moment of observation-, the higher is the masking-
related protection she might show. Masking is also a geography-dependent effect, which forces us to 
consider two masking parameters: 
  
mM  for Manaus and 
  
mS  for Salvador. The dependence of these 
parameters on age cannot be resolved, since all the cohorts analyzed in the study has approximately the 
same age. 
 
Additionally, if 
 
e(t )  describes the protection provided by the vaccine to a naive individual in absence of 
masking or blocking 
 
t  years after vaccination, we also need to describe how this protection is modified if the 
vaccine is applied to non-naive subjects. If an individual’s immune system has been stimulated prior to 
vaccination (either by masking like in cohort 3, or by a previous vaccine, like in cohort 4 before the second 
dose), and consequently she is partially protected against the disease, it is unrealistic to assume that the full 
effect of the new dose is additive [25].  Instead of that, our model considers that a vaccine dose applied on a 
previously protected individual will contribute up to resetting of the initial protection levels 
 
e(0), provided that 
no blocking takes place. This implies that, right after the school age vaccination, in cohort 3, if the vaccine is 
not blocked (
 
b = 0 , see below), it will have a protective effect 
 
!  e that will be concurrent with the masking 
protection 
 
m  so as to reduce the disease risk to 
 
1! " e [ ] 1! m[ ]x . Our estimation of 
 
!  e comes from assuming 
that such disease risk must equate what we would observe if a vaccine of full efficacy were applied on naive 
individuals, and observed 4.5 years later: 
 
 
1! " e [ ] 1!m[ ]x = 1! e(4.5)[ ]x# " e = e(4.5)!m1!m                   (1) 
 
Similarly, the school-age dose at cohort 4, will add to the protection provided by the newborn dose 
 
e(16) , an 
additional factor 
 
! ! e , To obtain 
 
! ! e , we assume that, if not blocked, the disease risk achieved by both 
vaccines together (
 
1! e(16)[ ] 1! " " e [ ]x  is equivalent to the disease risk reached by the same vaccine, if 
applied on unprotected inviduals, 4.5 years after vaccination: 
 
 
1! e(16)[ ] 1! " " e [ ]x = 1! e(4.5)[ ]x# " " e = e(4.5)! e(16)1! e(16)            (2) 
 
Finally, vaccine intrinsic efficacy can be blocked by prior ES; an effect that we model through the blocking 
probability 
 
b![0,1], where 
 
b = 0  means that no blocking appears, while 
 
b = 1  stands for a totally blocked 
vaccine, meaning that vaccinated individuals will only posses the protection level that they already had 
before vaccination. Blocking is also a geography-dependent factor, since it is considered a consequence of 
ES as well, which forces us to distinguish 
 
bM and 
 
bS  for Manaus and Salvador, respectively. Unlike masking, 
blocking does not depend on the age of the individuals at the moment of observation, but on their age at the 
moment of vaccination. In this case we study cohorts vaccinated at two moments in life –at birth and at the 
beginning of the trials- being the first of these cases (the newborn vaccination) considered blocking-free, as it 
is assumed that when the vaccine is applied immediately after birth, there is no place for prior ES.  
 
Taking all these effects into account, we are left with a set of six independent parameters 
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r 
P = e(4.5),e(16),mM ,bM ,mS ,bS{ } to describe the variability observed in the trials, either temporal or 
geographical, under the light of blocking and masking effects, concurrently. The temporal trends of the level 
of protection of each cohort are schematically shown in figure 3.  
 
 
 
Figure 3: Scheme for the temporal evolution of the level of protection for the 4 cohorts considered in 
the work, according to the different vaccination and ES possibilities. Cohort one: protection against 
disease of non-vaccinated individuals can only be due to masking, which is an increasing function 
with age. Cohort 2: Newborn vaccination cohort: individuals are vaccinated right after birth, which 
provides a protection that overcomes any possible masking effect, cannot be blocked by ES and 
wanes with time. Cohort 3: school age, first dose: masking, if present, can initially protect individuals. 
Then, at the moment of vaccination, if not blocked, the vaccine will overcome masking protection up 
to the initial value 
 
e(0), which then will wane. Cohort 4: School age re-vaccination cohort: after a 
newborn, unblocked vaccination, a second dose is applied, which, if not blocked, will reset the initial 
protection levels provided by the vaccine. The grey shaded area represents the age window of the 
individuals enrolled in the study. 
 
 
In the following, we will refer to this full model as model 1. In figure 2, we represent the variations on the 
disease rates provoked by each effect that takes place in each cohort according to model 1. Summing all the 
possible contributions to the development of active disease for each cohort, we derive the general disease 
rates characterizing each cohort of one city as follows: 
 
 
d1l = (1!ml )x
d2l = 1! e(16)[ ]x
d3l = 1! bl( ) 1! e(4.5)[ ]x + bl 1!ml( )x
d4l = 1! bl( ) 1! e(4.5)[ ]x + bl 1! e 16( )( )x
 (3) 
 
where the superscript indicates location, and
  
x the incidence rate observed in the population. 
 
From (3), it is immediate to derive the expressions for the observed efficacies 
 
e  of each trial according to 
model 1, which read as: 
 
 7 
 
M1 :
e Il = 1! d2l /d1l =
e(16)!ml
1!ml
e IIl = 1! d3l /d1l =
e(4.5)!ml
1!ml (1! b
l )
e IIIl = 1! d4l /d2l =
e(4.5)! e(16)
1! e(16) (1! b
l )
" 
# 
$ 
$ 
$ 
% 
$ 
$ 
$ 
                        (4) 
 
The system of equations (4) represents a full model for the vaccine efficacies observed during BCG-REVAC 
trials, which is based on the assumption that the sources of geographical variability for BCG’s performance 
are both masking and blocking effects. From the full model, two reduced versions can be conceived: a 
masking-free model (model 2 in the following) in which 
 
mM = mS = 0, and a blocking free model in which 
 
bM = bS = 0 (model 3). The efficacies associated to each trial, for models 2 and 3 straightforwardly read as 
follows: 
 
 
M2 :
e Il = e(16)
e IIl = e(4.5)(1! bl )
e IIIl =
e(4.5)! e(16)
1! e(16) (1! b
l )
" 
# 
$ 
$ 
% 
$ 
$ 
                                      (5) 
 
M 3 :
e Il =
e(16)!ml
1!ml
e IIl =
e(4.5)!ml
1!ml
e IIIl =
e(4.5)! e(16)
1! e(16)
" 
# 
$ 
$ 
$ 
% 
$ 
$ 
$ 
                                                  (6) 
 
By considering these three models, our approach allows quantifying and comparing the plausibility of 
blocking and masking hypotheses to potentially explain the variation in BCG efficacy trials observed in the 
controlled setup conceived in the BCG-REVAC trials, taking into account the non-linearities associated to 
each mechanism, which play a central role in the derivation of Equations (4-6).  
 
Models solution: parameters estimation and confidence intervals.  
 
In order to identify the set or sets of parameters yielding a best fit for the efficacies observed in BCG-REVAC 
trials, we compare the model prediction associated to any parameter set   
 
r 
P to a set of empirical probability 
distributions derived from BCG-REVAC data. From each of the confidence intervals reported in [6] we build a 
two-piece normal distribution [30] for each trial reported, centered in the reported values 
 
e il[ ]BCG!REVAC  (for 
location 
 
l ! Manaus,Salvador{ }  and trial 
 
i ! I, II, III{ }), and with asymmetric variances 
 
! i
l[ ]BCG"REVAC
±
 equal to 
one half the radius of the confidence intervals reported in [6], so, preserving the confidence levels of the 
intervals reported (see figure 1). 
 
Once the empirical distributions have been defined, for each possible set of parameters and for each of the 
six trials we define the Z-score associated to the model prediction as: 
 
  
 
Zil (
r 
P ) =
e il (
r 
P )[ ]mod ! e il[ ]BCG!REVAC
" i
l[ ]BCG!REVAC
±       (7) 
 
where 
 
! i
l[ ]BCG"REVAC
±
 will take each of its two possible values depending on the sign of  
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e il (
r 
P )[ ]mod ! e il[ ]BCG!REVAC( ) . From   
 
Zil (
r 
P ), we define the corresponding p-values   
 
pil[Zil (
r 
P )] as the probability 
of the empirical distributions reproducing BCG-REVAC data to have a Z-score 
  
˜ Z  so that 
  
 
˜ Z > Zil (
r 
P ) . This 
allows us to define the following likelihood function: 
 
  
 
L(
r 
P ) = pil[Zil (
r 
P )]
l ,i
!            (8) 
 
to maximize so as to identify the model’s parameters   
 
r 
P *  more likely to yield the BCG-REVAC results. The 
global landscape of   
 
L(
r 
P )  is explored using a hill-climbing algorithm designed to identify all possible local 
maxima in the space of parameters. Finally, a Levemberg-Marquardt algorithm is used to find a more 
accurate value of the global maximum, if the latter is unique. 
 
In order to estimate the confidence interval 
associated to our model estimation, the following 
numerical procedure is performed. First, and starting 
from the maximum likelihood estimate   
 
r 
P * , we move 
on each parameters’ axis until a value of 
 
L = 0.05  is 
reached in each case. We call this increment 
 
Aj  
(
 
j !(1,6) ) (see figure 4). These values are not 
symmetrical, again, and so we distinguish between 
 
Aj+  and 
 
Aj! . Using these asymmetric widths, we 
construct a two-piece normal distribution for every 
parameter [30], centred in 
 
Po  and having an 
asymmetric variance given by 
 
! j
± = cAj± , where 
  
c is 
a common modulation coefficient. Besides, the 
distribution is truncated at 1. Finally we numerically 
estimate 
 
c  by generating sets of points in the 
parameter space whose coordinates in each axis are 
obtained from the split normal distributions 
mentioned for an initial guess of 
  
c. Through an 
iterative process we search the value 
 
c = c*  for which 
a 95% of the points generated in the parameters 
space, yield efficacy estimations verifying 
 
L(P) > 0.05 . Once we have found the optimal value of the scaling coefficient, the reported uncertainty of the 
j-th parameter corresponds to 95% C.I. given the distributions we have used.   
 
 
RESULTS  
 
In order to find the set or sets of parameters yielding best estimates of BCG efficacies according to our 
models we have performed a series of numerical optimization procedures seeking for likelihood 
maximization. First, we are interested in addressing whether a unique likelihood maximum exists across the 
parameter space of each model or whether, on the contrary, there exist multiple minima associated to 
different, yet comparable values of   
 
L(
r 
P ) . This is an important question to address, as the existence of 
different maxima in a model would be eventually associated to the existence of different parameters sets 
describing vaccine’s properties all of them compatible with the general model formulation. To solve that 
question, we performed an iterative hill-climbing algorithm starting from 20,000 random points across the 
parameter space for each model. As it can be seen in figure 5, while model 2 presents a unique likelihood 
maximum (  
 
L(
r 
P *) = 0.53), models 1 and 3, which contemplates masking, fails at providing a univocal 
vaccine’s description associated to a unique solution from likelihood optimization.  
 
 
Figure 4: Confidence intervals estimation scheme. 
Degraded shades represent the joint probability density 
associated to the estimation of confidence intervals 
around the model best fit. The modulation coefficient 
  
c  is 
determined so as to make the brown area within the black 
line of 
 
L(P) = 0.05  to precisely accumulate the 95% of 
the total joint probability distribution. 
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Figure 5: Panels a,b,c: Hill climbing algorithm distributions for models 1, 2 and 3, respectively. 
Starting from a series of randomly distributed points in the parameter space (their coordinates 
distributions are represented in red), a random displacement following a uniform distribution in the 
parameter space within a hyper-cube of size 
 
! = 0.001  is attempted at each time step, and accepted 
only if it corresponds to an increasing of the likelihood function   
 
L(
r 
P ) . The algorithm stops when no 
further move is accepted after 
 
N = 107  rejected displacements (i.e. the function   
 
L(
r 
P )  reaches a 
maximum). In green, we see the peaked distribution of the end points of the algorithm around the 
solution of the models. Panels d and e: parameters cliff yielding quasi-constant values of maximum 
likelihood   
 
L(
r 
P *) = 0.79  for model 1 and   
 
L(
r 
P *) = 0.002  for model 3. As it can be seen in panel a and c, 
the model versions that contemplate masking are unable to provide a clear univocal vaccine 
description yielding maximum likelihood. The reason for this behavior is the existence of a region in 
the parameters space, represented in panel d and e, within which, likelihood is almost constant and 
close to its absolute maximum. 
 
 
Instead of that, as we can see in figure 5, panels a,c,d and e models 1 and 3 present a parameters cliff 
across which model’s likelihood is near to its maximum, and largely comparable (  
 
L(
r 
P *) = 0.79  for model 1, 
and   
 
L(
r 
P *) = 0.002  for model 2). Furthermore, a relative likelihood test comparing models 2 and 3 (that is, 
comparing blocking vs masking as exclusive mechanisms) yields a relative likelihood 
  
 
L3(
r 
P *) / L2 (
r 
P *) = 0.002/0.53 = 3.8 !10"3 , which, considering that both models share the same amount of 
parameters, highlights again the inability of masking to provide a picture for vaccine efficacy variation as 
accurate as blocking does, as we can also see in figure 1, where the best fit provided by each model is 
presented as well. 
 
If the analysis of model 3 and its comparison against model 2 allows us to discard masking as an 
autonomous mechanism able to explain the vaccine efficacy measured in the trials, it remains to be 
elucidated whether its consideration aside blocking in model 1 might still be able to significantly improve the 
fitting of the observed data. To answer this question, we conduct a simple likelihood ratio test in which the 
null and full models are, respectively models 2 and 1. From such test, we get that the statistic: 
 
! 2 = "2 ln L2 (P*) / L1(P*)( ) = 0.80 , is a chi-square distributed variable with 2 degrees of freedom (difference 
between number of parameters of models 1 and 2) under the null, containing blocking alone, model. The 
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obtained value does not allow to discard it even with a 50% confidence (
 
X 2 (p = 0.5 ,df = 2) = 1.39 ), which 
indicates that masking is not just unable to provide an acceptable description of the observed data by itself 
but also makes no significant contribution to explain the variations in vaccine efficacies observed in the trials 
under study, when considered in addition to blocking. This is also reflected in the close estimates that are 
found for blocking parameters in models 1 and 2 (see table 1 and figure 5). Besides, if we analyze the 
combination of parameters that formed the cliff of maximum likelihood in model 1, we see that it consists in 
very similar levels of masking for the two different cities, which enters into conflict with the mentioned 
correlation between ES effects and closeness to equator. 
 
 
Parameter Model 2 (only blocking) 
 
e(4.5)  57.7%  (46.8% to 68.6%) 
 
e(16)  37.6% (29.3% to 45.8%) 
 
bM  96.4% (51.9% to 99.8%) 
 
bS  41.1% (14.2% to 68.0%) 
 
Table 1: Optimal parameters of model 2. Models 1 and 3 are unable to 
provide a unique parameter set yielding maximum likelihood. 
 
 
In summary, our results point to blocking as the only plausible source of vaccine efficacy variation between 
the two mechanisms considered, validating the qualitative interpretation of the BCG-revac outcomes by 
Barreto et al. [8]. The best fit of model 2 yields a likelihood   
 
L(
r 
P *) = 0.53, which corresponds to moderate 
blocking levels in Salvador (
 
bS = 0.41 c.i. [0.14,0.68]) and to almost total blocking in Manaus (
 
bS = 0.96  c.i. 
[0.52,1.00]), results that are, in turn, consistent with the assumed correlation between ES action strength and 
closeness to equator. 
 
 
DISCUSSION 
 
Understanding the mechanisms driving ES effects on BCG performance is a crucial task in the agenda 
towards the development of new tuberculosis vaccines. In this work, we have proposed a mathematical 
model that allows the quantitative evaluation of these two effects based on the BCG-REVAC trials performed 
in Brazil [8]. We have seen that the divergence in the measured efficacies of the trials is explained with high 
values of blocking, which concur with the qualitative discussion made in Barreto, M.L. et al. [8]. Furthermore, 
we have also observed for the first time that no alternative behavior of BCG is compatible with the observed 
data within the context of a model in which BCG’s variability is entirely attributed to ES sensitization. 
 
Admittedly, the range of applications of the results here exposed must be restricted to the provision of a 
plausible explanation for the efficacy variation patterns observed within the context of BCG-REVAC studies. 
Therefore, its quantitative conclusions shouldn’t be extrapolated beyond this specific context. The analysis of 
new, hypothetical trials data similarly structured, conducted in other geographical areas, could certainly yield 
different results, both in terms of the values for the intrinsic vaccine efficacies and also in what regards the 
relative weights of masking and blocking mechanisms and their correlation with latitude. An additional 
limitation of BCG-REVAC data is due to the restriction of trials’ endpoints to diseased and not diseased 
individuals, without measuring infection as a third relevant outcome. This limitation prevents us to address 
the relevant question of whether the vaccine is being blocked in its protective role against infection, or if, 
instead, blocking interferes more intensely with the vaccine’s performance at reducing the progression rates 
from latency to active disease. As a general conclusion, more studies are needed to evaluate how general 
are the patterns found by BCG-revac trials, with the ultimate goal of assessing a positive explanation to the 
long lasting problem of BCG efficacy variation patterns. In this work, our aim is to provide a methodology 
useful for the analysis of such hypothetical studies.  
 
The crucial implications of discriminating and quantifying masking and blocking effects for TB vaccine 
development are twofold. On one hand, understanding the range, and causes behind the variations of BCG 
efficacy is essential [31], as the efficacy of any novel vaccine will be measured against BCG. On the other 
hand, depending on where a new vaccine is applied and how old are the target populations, masking or 
blocking effects could affect new vaccines too. 
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Figure 6: Scheme of the basis for evaluation of anti tuberculosis vaccines in absence of universally reliable 
protection correlates. First stage: design of vaccine efficacy determination clinical trials: the age of the cohorts 
must be elected taking into account that prior exposure to mycobacteria –either environmental, M. tuberculosis 
after exposure or even prior TST or also BCG– may corrupt the observed vaccine efficacies. Second stage: 
vaccine impact evaluations: bulk, short term and long term impact forecasts should be equally considered, as 
well as age-distributed impacts in terms of cases, infections and casualties prevented. 
 
 
These issues affect different stages of the vaccine development pipeline, as sketched in figure 6. In the first 
place, during the process of vaccine evaluation in the context of clinical trials, studies of new tuberculosis 
vaccines should account for the possibility that prior infection may mask or (more likely) block their effects 
[5]. In this sense, and even if a new vaccine targeting TB in adolescents and adults rather than any other age 
group is expected to have the quickest impact on disease transmission and control, before we address the 
question of impact of novel vaccines, it is essential to know if the vaccine is more efficacious with respect to 
the current BCG. The most reliable way of knowing whether a new vaccine works better than BCG is by 
conducting an efficacy trial in a naive population without previous environmental sensitization (e.g., previous 
BCG vaccination, mycobacterial infection and/or TB contact) in order to avoid possible effects of masking or 
blocking [7,8,25].  It should be remarked that, beyond ES, as considered in this work, the very prior 
vaccination with BCG might trigger an additional blocking effect on further revaccination, specially when 
talking about live attenuated vaccines conceived as BCG’s alternatives rather than as BCG boosters. This 
scenario would make clinical trials of these novel vaccines even more unreliable when performed on already 
vaccinated populations. 
 
Furthermore, and once the efficacy estimation is complete, in order to produce any reliable vaccine impact 
and cost-effectiveness forecast, modelling scenarios contemplating ES deleterious effects on Tuberculosis 
vaccines are mandatory. The fact that, according to our analysis, blocking emerges as the driving effect 
behind BCG variability poses a potential pitfall to any vaccination strategy focused on individuals older than 
those analyzed here, very critically, most strategies conceived so far for booster vaccines.  This is especially 
worth noticing because blocking, unlike masking, is not supposed to degrade the vaccine-induced protection 
obtained further during life by individuals immunized promptly after birth. Again, even if immunizing 
adolescents is thought to provide better impacts than vaccination strategies focused on younger age-
segments, if such a novel vaccine is affected by blocking just as BCG is, then its impact will decrease in a 
way that, given the high blocking levels here identified, might even revert the comparison. As suggested by 
Helen McShane “we should optimize deployment of BCG to administration as close to birth as possible” [31], 
this should be the case for new priming live vaccines candidates based on BCG replacement strategies [6]. 
 
Taken all together, our results highlight the need for measuring ES effects on novel vaccines performance, 
as well as of diversifying vaccination strategies. 
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